Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 393

1.

Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.

Damman P, Abdel-Wahab M, Möllmann H, Richardt G, Chevalier B, Barragan P, Tijssen JG, Underwood P, Hamm CW.

J Invasive Cardiol. 2012 Oct;24(10):495-502.

2.

Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.

J Interv Cardiol. 2013 Apr;26(2):153-62. doi: 10.1111/j.1540-8183.2013.12016.x. Epub 2013 Jan 31.

PMID:
23363439
3.

Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.

Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.

JACC Cardiovasc Interv. 2014 May;7(5):471-81. doi: 10.1016/j.jcin.2013.12.201.

4.

Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.

Park KW, Lee JM, Kang SH, Ahn HS, Yang HM, Lee HY, Kang HJ, Koo BK, Cho J, Gwon HC, Lee SY, Chae IH, Youn TJ, Chae JK, Han KR, Yu CW, Kim HS.

J Am Coll Cardiol. 2013 Feb 5;61(5):536-44. doi: 10.1016/j.jacc.2012.11.015. Epub 2012 Dec 26.

5.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

6.

Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.

Li XT, Sun H, Zhang DP, Xu L, Ni ZH, Xia K, Liu Y, Chi YH, He JF, Li WM, Wang HS, Wang LF, Yang XC.

Coron Artery Dis. 2014 Aug;25(5):405-11. doi: 10.1097/MCA.0000000000000098.

PMID:
24584031
7.

Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.

Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Jo SH, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Gwon HC, Jang YS, Kim HS.

J Am Coll Cardiol. 2011 Oct 25;58(18):1844-54. doi: 10.1016/j.jacc.2011.07.031.

9.

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH.

J Am Coll Cardiol. 2012 Apr 10;59(15):1350-61. doi: 10.1016/j.jacc.2012.01.008. Epub 2012 Feb 15.

10.

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, van Houwelingen KG, de Man FH, Linssen GC, Saïd SA, Nienhuis MB, Löwik MM, Verhorst PM, van der Palen J, von Birgelen C.

J Am Coll Cardiol. 2013 Jun 18;61(24):2406-16. doi: 10.1016/j.jacc.2013.04.005. Epub 2013 Apr 16.

11.

Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.

Hannan EL, Zhong Y, Wu C, Walford G, Holmes DR Jr, Jacobs AK, Stamato NJ, Venditti FJ, Sharma S, Fergus I, King SB 3rd.

Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1097-105. doi: 10.1002/ccd.24512. Epub 2013 Mar 8.

PMID:
22707353
12.

4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S; RESOLUTE All-Comers Investigators.

J Am Coll Cardiol. 2014 Apr 29;63(16):1617-25. doi: 10.1016/j.jacc.2013.12.036. Epub 2014 Feb 13.

13.

Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.

Mahmoudi M, Delhaye C, Wakabayashi K, Ben-Dor I, Gonzalez MA, Maluenda G, Gaglia MA Jr, Torguson R, Xue Z, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2011 Jun 15;107(12):1757-62. doi: 10.1016/j.amjcard.2011.02.330. Epub 2011 Apr 15.

PMID:
21497782
14.

Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.

Jang SJ, Park DW, Kim WJ, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1106-14. doi: 10.1002/ccd.24603. Epub 2013 Feb 9.

PMID:
22899589
15.

Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.

Shiomi H, Kozuma K, Morimoto T, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Uematsu M, Tarutani Y, Fujii K, Simonton CA, Kimura T; RESET Investigators.

Circ Cardiovasc Interv. 2014 Jun;7(3):343-54. doi: 10.1161/CIRCINTERVENTIONS.113.001322. Epub 2014 May 6.

16.

Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.

Omar A, Torguson R, Kitabata H, Pendyala LK, Loh JP, Magalhaes MA, Satler LF, Suddath WO, Pichard AD, Waksman R.

Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1053-60. doi: 10.1002/ccd.25469. Epub 2014 Aug 5.

PMID:
24619969
17.

2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial.

Jensen LO, Thayssen P, Christiansen EH, Tilsted HH, Maeng M, Hansen KN, Kaltoft A, Hansen HS, Bøtker HE, Krusell LR, Ravkilde J, Madsen M, Thuesen L, Lassen JF; SORT OUT IV Investigators.

J Am Coll Cardiol. 2012 Sep 25;60(13):1140-7. doi: 10.1016/j.jacc.2012.07.004. Epub 2012 Sep 5.

18.

Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).

Lee JM, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Park JS, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS.

Am J Cardiol. 2014 Nov 1;114(9):1329-38. doi: 10.1016/j.amjcard.2014.07.065. Epub 2014 Aug 12.

PMID:
25217457
19.

The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.

Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH Jr, Coleman PS, Stoler RC, Papadakos S, Cutlip DE, Mauri L, Kandzari DE; ENDEAVOR IV Investigators.

JACC Cardiovasc Interv. 2013 Apr;6(4):325-33. doi: 10.1016/j.jcin.2012.12.123. Epub 2013 Mar 20.

20.

Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.

Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schömig A, Mehilli J; ISAR-TEST 4 Investigators.

J Am Coll Cardiol. 2011 Sep 20;58(13):1325-31. doi: 10.1016/j.jacc.2011.06.027.

Supplemental Content

Support Center